There is a growing movement within the industry to focus on patientcentricity in clinical trials. The FDA and EMA have introduced requirements to include patient input into protocol design, as well as providing lay summaries to patients at the end of trials. Rosamund Round at Parexel demonstrates how the COVID-19 crisis has highlighted the importance of preparing and executing trials in a patient-centric way to ensure they have access to clinical trials, even in potentially unpredictable situations.